Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

10.95
0.0000
Pre-market: 12.001.05+9.59%04:48 EST
Volume:- -
Turnover:- -
Market Cap:1.69B
PE:- -
High:72.80
Open:72.80
Low:72.80
Close:- -
52wk High:73.06
52wk Low:21.51
Shares:154.74M
Float Shares:132.00M
Volume Ratio:2.78
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):-4.9715
ROE:-43.98%
ROA:-26.47%
PB:1.00
PE(LYR):-2.20

Loading ...

Pipeline Achievement Exceeds Expectations: XTALPI (02228) Secures Tens of Millions in HKD Milestone Payment as AI+RNA Drug RTX-117 Gains Clinical Approvals in China and US

Stock News
·
Jan 14

Converge Bio Secures $25 Million Funding with Backers Including Bessemer Ventures and Executives from Meta, OpenAI, and Wiz

Deep News
·
Jan 13

Novartis eyes more bolt-on acquisitions, CEO says

Reuters
·
Jan 13

ValiRx Strikes RNA Helicase Inhibitor Deal with McGill and IRICoR to Drive Asset-Level Growth

TIPRANKS
·
Jan 09

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

GlobeNewswire
·
Jan 08

Entrada Therapeutics reports progress across development portfolio

TIPRANKS
·
Jan 08

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

GlobeNewswire
·
Jan 08

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 05

The Year-End 2025 Biotech Rally And What It Means For 2026

Benzinga_recent_news
·
Dec 31, 2025

RNA drug developer Ribo Passes Hong Kong Listing Hearing, Kicking Off IPO

Benzinga_recent_news
·
Dec 26, 2025

Evercore ISI Downgrades Avidity Biosciences to In Line From Outperform, Adjusts Price Target to $72 From $65

MT Newswires Live
·
Dec 18, 2025

CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

GlobeNewswire
·
Dec 18, 2025

Avidity Biosciences Accelerates Executive Payouts Ahead of Novartis Merger

Reuters
·
Dec 18, 2025

Scientists Extract New Secrets of the Woolly Mammoth -- WSJ

Dow Jones
·
Dec 17, 2025

Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says

MT Newswires Live
·
Dec 11, 2025

Assessing Avidity Biosciences (RNA) Valuation After Its Strong Multi‑Year Share Price Rally

Simply Wall St.
·
Dec 08, 2025

ProQR to Participate in 8th Annual Evercore Healthcare Conference

GlobeNewswire
·
Dec 01, 2025

Will FDA Accelerated Pathway for Delpacibart Zotadirsen Reshape Avidity Biosciences' (RNA) Rare Disease Trajectory?

Simply Wall St.
·
Nov 27, 2025

BUZZ-Sarepta rises after U.S. FDA clears study of muscle-wasting disease drug

Reuters
·
Nov 25, 2025

Silexion Therapeutics completes toxicology studies for SIL204

TIPRANKS
·
Nov 25, 2025